APOC1 / Apolipoprotein C I Antibody (C-Terminus)
Goat Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, E |
---|---|
Primary Accession | P02654 |
Reactivity | Human |
Host | Goat |
Clonality | Polyclonal |
Calculated MW | 9kDa |
Dilution | ELISA (1:8000), IHC-P (3.75 µg/ml), |
Gene ID | 341 |
---|---|
Other Names | Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, Truncated apolipoprotein C-I, APOC1 |
Target/Specificity | Human APOC1 / Apolipoprotein CI. |
Reconstitution & Storage | Store at -20°C. Minimize freezing and thawing. |
Precautions | APOC1 / Apolipoprotein C I Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | APOC1 |
---|---|
Function | Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein. |
Cellular Location | Secreted. |
Tissue Location | Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.
References
Knott T.J.,et al.Nucleic Acids Res. 12:3909-3915(1984).
Lauer S.J.,et al.J. Biol. Chem. 263:7277-7286(1988).
Freitas E.M.,et al.DNA Seq. 9:89-100(1998).
Nickerson D.A.,et al.Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.